RxDoctor Payments Data

Pamela Fazio, DO

Nuclear Cardiology · Moorestown, NJNPI 1235623810

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,073 of the $2,475 with a category attached, or 83.7%. 19 manufacturers reported payments, led by Biotronik Inc. at 37.5% of the total. That places this record below the midpoint for nuclear cardiology clinicians in NJ, where the typical reported total is $3,343.

$2,475in general payments, 2019–2025

Across 60 payments — averaging $41.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$929
  • Abbott$929
  • Kestra Medical Technology Services, Inc.$106
  • Novartis$101
  • Boston Scientific$65
  • AstraZeneca$51
  • plus $295 from 13 others

What the payments were for

  • Food & beverage$2,07384%
  • Education$40216%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,475 in reported general payments places this provider in the 35th percentile of 34 nuclear cardiology providers in New Jersey.

See all nuclear cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$63,544
Medicare patients
379
Services billed
903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$17,501
Metoprolol Succinate50$666
Atorvastatin Calcium52$486
Rosuvastatin Calcium13$388
Bumetanide15$332
Carvedilol19$228
Olmesartan Medoxomil11$160
Amlodipine Besylate38$135
Losartan Potassium31$118
Furosemide21$82
Metoprolol Tartrate15$59
Spironolactone11$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$17,50121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 34 nuclear cardiology providers in New Jersey.

Other nuclear cardiology in Moorestown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →